Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Production of therapeutic levels of human FIX-R338L by engineered B cells using GMP-compatible medium

19 Sept 2023

Abstract excerpt

B cells can differentiate into plasmablast and plasma cells, capable of producing antibodies for decades. Gene editing using zinc-finger nucleases (ZFN) enables the engineering of B cells capable of secreting sustained and high levels of therapeutic proteins. In this study, we established an advanced in vitro good manufacturing practice-compatible culturing system characterized by robust and consistent expansion...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37790246
DOI: 10.1016/j.omtm.2023.101111

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Production of therapeutic levels of human FIX-R338L by engineered B cells using GMP-compatible mediumPMID 37790246Read ↗

Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells.Semantic proximity Read ↗

Scalable GMP-compliant gene correction of CD4+ T cells with IDLV template functionally validated in vitro and in vivoSemantic proximity Read ↗

In vivo genome editing of the albumin locus as a platform for protein replacement therapySemantic proximity Read ↗

First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I/II and hemophilia BSemantic proximity Read ↗

Effective gene therapy for haemophilic mice with pathogenic factor IX antibodiesSemantic proximity Read ↗

<i>In vivo</i> production of an anti-HIV antibody from primate hematopoietic cells by non-viral knock-inSemantic proximity Read ↗

B Lymphocyte Protein Factories produced by Hematopoietic Stem Cell Gene EditingSemantic proximity Read ↗

Coagulation Factor IX for Hemophilia B TherapySemantic proximity Read ↗

Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia BSemantic proximity Read ↗

Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration.Semantic proximity Read ↗

Engineered hematopoietic stem cells give rise to therapeutic antibody secreting B cellsSemantic proximity Read ↗

Robust ZFN-mediated genome editing in adult hemophilic miceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.